PERIPHERAL-BLOOD STEM-CELLS MOBILIZED FROM PATIENTS WITH ACUTE MYELOID-LEUKEMIA HAVE DIFFERENT PLATELET REPOPULATING ABILITIES COMPARED WITH THOSE MOBILIZED FROM PATIENTS WITH OTHER DISEASES

Citation
Mm. Roberts et al., PERIPHERAL-BLOOD STEM-CELLS MOBILIZED FROM PATIENTS WITH ACUTE MYELOID-LEUKEMIA HAVE DIFFERENT PLATELET REPOPULATING ABILITIES COMPARED WITH THOSE MOBILIZED FROM PATIENTS WITH OTHER DISEASES, Bone marrow transplantation, 18(1), 1996, pp. 41-45
Citations number
15
Categorie Soggetti
Hematology,Oncology,Immunology,Transplantation
Journal title
ISSN journal
02683369
Volume
18
Issue
1
Year of publication
1996
Pages
41 - 45
Database
ISI
SICI code
0268-3369(1996)18:1<41:PSMFPW>2.0.ZU;2-E
Abstract
Peripheral blood stem cell (PBSC) transplantation gives rapid recovery of neutrophils and platelets and sustained haemopoiesis. However in p atients with acute myeloid leukaemia (AML) platelet recovery has a dis tinctive rapid rise and then secondary fall between 3 to 8 weeks post- transplant. This study compares platelet and neutrophil recovery after PBSC transplantation in 15 patients with AML and 29 patients with oth er diseases consecutively transplanted in a single unit. PBSC were col lected during recovery from consolidation chemotherapy in AML patients and after cyclophosphamide or cytokine administration in the other pa tient groups, Mononuclear cell numbers collected were similar but CFU- GM numbers were greater from the AML patients, A significant secondary fall occurred only in the platelet count and only in AML patients, Lo ng-term recovery of the platelet count was the same in AML as in the o ther patients, In AML patients, the fall was the same in the long term remitters as in those who eventually relapsed, Previous studies have not demonstrated a difference in type of precursors mobilized by diffe ring methods, but have not included AML patients. Megakaryocyte precur sors were assayed in this study and showed no consistent differences i n number between patient groups however pre-progenitor assays are not yet established especially in the megakaryocytic lineage, The possible explanation for this secondary fall in AML patients is discussed.